Palvella Therapeutics
PVLA
98 hedge funds and large institutions have $93M invested in Palvella Therapeutics in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 28 reducing their positions, and 21 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 28
0.02% less ownership
Funds ownership: 0.82% → 0.81% (-0.02%)
7% less funds holding
Funds holding: 105 → 98 (-7)
24% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 21
53% less capital invested
Capital invested by funds: $199M → $93M (-$106M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $84K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$7.2M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.8M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.42M |
| 4 |
Renaissance Technologies
New York
|
+$2.33M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$13.8M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$5.15M |
| 3 |
Millennium Management
New York
|
-$3.04M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$2.96M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$1.01M |
PVLA Hedge Fund Activity: Q4 2018 in Review
98 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2018, worth a combined $93M — down 53% from $199M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of PVLA and 16 opened new positions — a net loss of 5 holders — while 28 trimmed existing stakes and 36 added.
The largest buyer was BVF Inc, adding an estimated $7.2M. The largest seller was OrbiMed, exiting entirely with an estimated $13.8M sold.
- 98 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2018, down from 105 in Q3 2018.
- Funds reported $93M of Palvella Therapeutics stock for Q4 2018, down 53% quarter-over-quarter.
- 16 funds opened new Palvella Therapeutics positions in Q4 2018 and 21 closed out, a net change of -5 holders.
- The largest Palvella Therapeutics buyer in Q4 2018 was BVF Inc, an estimated $7.2M added.
- The largest Palvella Therapeutics seller in Q4 2018 was OrbiMed, an estimated $13.8M sold.
Based on aggregated 13F filings for Q4 2018.